Involvement of multiple efflux transporters in hepatic disposition of fexofenadine

Molecular Pharmacology

Volumn 73, Issue 5, 2008, Pages 1474-1483

  Matsushima, Soichiro ^a   Maeda, Kazuya ^a   Hayashi, Hisamitsu ^a   Debori, Yasuyuki ^a   Schinkel, Alfred H ^b   Schuetz, John D ^c   Kusuhara, Hiroyuki ^a   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BILE SALT; BILE SALT EXPORT PUMP; BREAST CANCER RESISTANCE PROTEIN; FEXOFENADINE; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTING PROTEIN 1B3; PITAVASTATIN; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCB11 PROTEIN, HUMAN; ABCC4 PROTEIN, HUMAN; BILE ACID; CARRIER PROTEIN; DRUG DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3; QUINOLINE DERIVATIVE; RECOMBINANT PROTEIN; TERFENADINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BILE FLOW; BILIARY EXCRETION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EXCRETION; DRUG POTENTIATION; FLOW RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STEADY STATE; TRANSCYTOSIS; UPREGULATION; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; CELL LINE; DOG; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; SECRETION; TRANSPORT AT THE CELLULAR LEVEL;

ADENOSINE TRIPHOSPHATE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CELL LINE; DOGS; GENE EXPRESSION REGULATION; GLUTATHIONE; HUMANS; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; QUINOLINES; RECOMBINANT PROTEINS; TERFENADINE;

EID: 42449132256     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.041459     Document Type: Article

References (41)

1. Adachi Y, Kobayashi H, Kurumi Y, Shouji M, Kitano M, and Yamamoto T (1991) Bilirubin diglucuronide transport by rat liver canalicular membrane vesicles: stimulation by bicarbonate ion. Hepatology 14:1251-1258.
2. Akita H, Suzuki H, Hirohashi T, Takikawa H, and Sugiyama Y (2002) Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res 19:34-41.
3. Borst P, de Wolf C, and van de Wetering K (2007) Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 453:661-673.
4. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, and Thompson RJ (2002) The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 123:1649-1658.
5. Chu XY, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, Wang RW, Yabut J, Hartley DP, Evans DC, et al. (2006) Characterization of mice lacking the multi-drug resistance protein MRP2 (ABCC2). J Pharmacol Exp Ther 317:579-589.
6. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
7. Elferink RO and Groen AK (2002) Genetic defects in hepatobiliary transport. Biochim Biophys Acta 1586:129-145.
8. Hayashi H, Takada T, Suzuki H, Akita H, and Sugiyama Y (2005) Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11. Hepatology 41:916-924.
9. Hirano M, Maeda K, Hayashi H, Kusuhara H, and Sugiyama Y (2005a) Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther 314:876-882.
10. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, and Sugiyama Y (2005b) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800-807.
11. Hirohashi T, Suzuki H, Ito K, Ogawa K, Kume K, Shimizu T, and Sugiyama Y (1998) Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats. Mol Pharmacol 53:1068-1075.
12. Hirohashi T, Suzuki H, and Sugiyama Y (1999) Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 274:15181-15185.
13. Hirohashi T, Suzuki H, Takikawa H, and Sugiyama Y (2000) ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 275:2905-2910.
14. Hoffmann U and Kroemer HK (2004) The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab Rev 36:669-701.
15. Ishiguro N, Maeda K, Saito A, Kishimoto W, Matsushima S, Ebner T, Roth W, Igarashi T, and Sugiyama Y (2008) Establishment of a set of double transfectants co-expressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 36:796-805.
16. Keitel V, Burdelski M, Warskulat U, Kuhlkamp T, Keppler D, Haussinger D, and Kubitz R (2005) Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 41:1160-1172.
17. König J, Rost D, Cui Y, and Keppler D (1999) Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29:1156-1163.
18. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, et al. (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A 96:6914-6919.
19. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, and Schuetz JD (2000) Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol 57:24-35.
20. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, et al. (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612-7621.
21. Lippert C, Ling J, Brown P, and Burmaster S (1995) Mass balance and pharmacokinetics of MDL 16,455A in the healthy, male volunteers. Pharmacol Res (N Y) 12:S-390.
22. Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, and Elferink RO (2005) Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 42:1091-1098.
23. Matsushima S, Maeda K, Ishiguro N, Igarashi T, and Sugiyama Y (2008) Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36:663-669.
24. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, and Sugiyama Y (2005) Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314:1059-1067.
25. Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, Hagey L, Schuetz JD, and Boyer JL (2006) Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 43:1013-1021.
26. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, and Schinkel AH (2005) The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67:1758-1764.
27. Niinuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, and Sugiyama Y (1999) Primary active transport of organic anions on bile canalicular membrane in humans. Am J Physiol 276:G1153-G1164.
28. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, and Borst P (2003) Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63:1094-1103.
29. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, and Keppler D (2003) Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38:374-384.
30. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, and Sugiyama Y (2005) Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33:1477-1481.
31. Suzuki H and Sugiyama Y (1998) Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin Liver Dis 18:359-376.
32. Suzuki M, Suzuki H, Sugimoto Y, and Sugiyama Y (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278:22644-22649.
33. Tahara H, Kusuhara H, Fuse E, and Sugiyama Y (2005) P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 33:963-968.
34. Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, Raub TJ, and Brouwer KL (2008) Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos 36:61-64.
35. Van Aubel RA, Koenderink JB, Peters JG, Van Os CH, and Russel FG (1999) Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. Mol Pharmacol 56:714-719.
36. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13:595-603.
37. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, and Schinkel AH (2003) The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo[ 4,5-b]pyridine. Cancer Res 63:6447-6452.
38. Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, et al. (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319-327.
39. Zelcer N, Saeki T, Reid G, Beijnen JH, and Borst P (2001) Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276:46400-46407.
40. Zelcer N, van de Wetering K, de Waart R, Scheffer GL, Marschall HU, Wielinga PR, Kuil A, Kunne C, Smith A, van der Valk M, et al. (2006) Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 44:768-775.
41. Zeng H, Chen ZS, Belinsky MG, Rea PA, and Kruh GD (2001) Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res 61:7225-7232.